OncoMatch/Clinical Trials/NCT07046923
A Study of LY4175408 in Participants With Advanced Cancer
Is NCT07046923 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments including LY4175408 and Pembrolizumab for carcinoma, non-small-cell lung.
Treatment: LY4175408 · Pembrolizumab · Carboplatin · Cisplatin — The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could last up to 4 years.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Endometrial Cancer
Triple-Negative Breast Cancer
Breast Carcinoma
Biomarker criteria
Required: EGFR wild-type
NSCLC with no known actionable genomic alterations
Required: ALK wild-type
NSCLC with no known actionable genomic alterations
Required: ROS1 wild-type
NSCLC with no known actionable genomic alterations
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: protein tyrosine kinase 7 antibody-drug conjugate with topoisomerase I inhibitor payload
Prior treatment with a protein tyrosine kinase 7 (PTK7) antibody-drug conjugate (ADC) with a topoisomerase I inhibitor as payload
Cannot have received: topoisomerase I-based antibody-drug conjugate
Prior topoisomerase I-based ADCs are not allowed in cohorts A2, B1 or B2
Lab requirements
Cardiac function
Significant cardiovascular disease; QTcF > 470 ms
Significant cardiovascular disease. Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) > 470 milliseconds (ms)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford Medicine Cancer Center · Stanford, California
- Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute · Orlando, Florida
- Florida Cancer Specialists - Sarasota · Sarasota, Florida
- The University of Chicago Medical Center (UCMC) · Chicago, Illinois
- Community Health Network · Indianapolis, Indiana
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07046923 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior protein tyrosine kinase 7 antibody-drug conjugate with topoisomerase I inhibitor payload, topoisomerase I-based antibody-drug conjugate disqualifies patients from enrollment.
Does this trial require EGFR?
Yes, EGFR wild-type is a required biomarker for enrollment.
Does this trial require ALK?
Yes, ALK wild-type is a required biomarker for enrollment.
Does this trial require ROS1?
Yes, ROS1 wild-type is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify